• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cross-clade protective immune responses of NS1-truncated live attenuated H5N1 avian influenza vaccines

tetano

Editor, Senior Moderator
Vaccine. 2015 Nov 27. pii: S0264-410X(15)01694-1. doi: 10.1016/j.vaccine.2015.11.045. [Epub ahead of print]
[h=1]Cross-clade protective immune responses of NS1-truncated live attenuated H5N1 avian influenza vaccines.[/h] Shi S[SUP]1[/SUP], Chen S[SUP]2[/SUP], Han W[SUP]2[/SUP], Wu B[SUP]2[/SUP], Zhang X[SUP]2[/SUP], Tang Y[SUP]2[/SUP], Wang X[SUP]2[/SUP], Zhu Y[SUP]2[/SUP], Peng D[SUP]3[/SUP], Liu X[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] H5N1 highly pathogenic avian influenza (HPAI) has raised global concern for causing huge economic losses in poultry industry, and an effective vaccine against HPAI is highly desirable. Live attenuated influenza vaccine with trunctated NS1 protein as a potential strategy will extremely useful for improving immune efficacy.
[h=4]METHODS:[/h] A series of H5N1 avian influenza virus reassortants harboring amino-terminal 48, 70, 73, and 99 aa in NS1 proteins, along with a modified low pathogenic HA protein were generated, and named as S-HALo/NS48, S-HALo/NS70, S-HALo/NS73, and S-HALo/NS99, respectively. In addition, their biological and immunological characteristics were further analyzed.
[h=4]RESULTS:[/h] The viruses S-HALo/NS70, S-HALo/NS73, and S-HALo/NS99, but not S-HALo/NS48, had a comparable growth property with the full-length NS1 virus, S-HALo/NSFu. Mice and chickens studies demonstrated that the viruses with truncated NS1 protein were further attenuated when compared to the virus S-HALo/NSFu. Vaccination with the virus S-HALo/NS73 in chickens induced significant cross-protection against homologous clade 2.3.4 H5 virus and heterologous clade 7.2, 2.3.2.1, and 2.3.4.4 H5 viruses.
[h=4]CONCLUSION:[/h] A 70-aa amino-terminal fragment of NS1 protein may be long enough for viral replication. The recombinant virus S-HALo/NS73 is a broad-spectrum live attenuated H5N1 avian influenza vaccine candidate in chickens.
Copyright ? 2015. Published by Elsevier Ltd.


[h=4]KEYWORDS:[/h] Cross-protection; H5N1 avian influenza; Live attenuated vaccine; NS1

PMID: 26638027 [PubMed - as supplied by publisher]
 
Back
Top Bottom